What makes C-Diff superbug deadly?

March 02, 2009

MAYWOOD, Ill. - A major breakthrough about the potentially deadly superbug Clostridium difficile (C-diff) could lead to new ways to combat the bacterium, according to a study to be published March 1 in the journal Nature.

The study reveals that for decades researchers have been focusing on the wrong toxin that is released by the bacteria in the colon. The toxin can cause severe diarrhea and life-threatening colitis that could lead to the surgical removal of the colon.

"For 20 years, we have been focusing on Toxin A. But it turns out the real culprit is Toxin B," said study co-author Dr. Dale Gerding. "This is a major finding in how C-diff causes disease in humans. It completely flips our whole concept of what the important toxin is with this disease."

Gerding is a professor of medicine, division of infectious diseases, Loyola University Chicago Stritch School of Medicine, Maywood, Ill., and associate chief of staff for Research, Hines VA Hospital.

C-diff is a spore-forming bacterium that was discovered in 1978 to be the cause of antibiotic-associated diarrhea and colitis. It is rapidly spreading through health-care facilities around the globe. When the normal bacteria that live in the colon are disturbed, usually as a result of antibiotic treatment, and a patient ingests C-diff spores, the bacteria can multiply and release the two toxins.

C-diff sickens about 500,000 Americans a year, contributing to 15,000 to 20,000 deaths, The epidemic strain has been found in 38 states, including Illinois. It now rivals the superbug known as MRSA as one of the top emerging disease threats to humans. Since its discovery, C-diff has grown increasingly resistant to antibiotics. Though it is appearing more often in younger people, those 65 years and older face a greater risk of developing infection from C-diff and have more severe outcomes and higher death rates.

Symptoms of C-diff include profuse diarrhea and abdominal pain and distention of the abdomen. An infection is also frequently accompanied by fever, nausea and dehydration. In some rare cases blood may be present in the stool. The infection is spread by spores that contaminate the hospital environment and hands of healthcare workers who can transmit the spores to patients. The resistance of the spores to hospital cleaning agents and to alcohol hand disinfectants makes it extremely difficult to eradicate.

Gerding noted that a human clinical trial using a drug that bound Toxin A more than it bound Toxin B failed to treat C-diff effectively.

"There's probably a good reason why the trial failed," Gerding said. "We now know that Toxin B should have been the primary target." -

The study has major implications for the future development of treatments and preventative measures for C-diff, said Gerding and co-author Dr. Stuart Johnson, associate professor of medicine, division of infectious diseases, Loyola University Chicago Stritch School of Medicine.

"The more you understand the way an organism causes disease, the better you can target treatment or preventative measures," said Johnson, who has treated dozens of C-diff patients.

The breakthrough in the study came after co-authors in Australia engineered mutant strains of the bacteria that were tested by Gerding and other Loyola researchers.

"It turns out that in the strain in which Toxin A was knocked out, the organism was fully virulent. It caused disease," Johnson said. "When they knocked the Toxin B out in another set of experiments, the organism didn't cause disease. This is probably the best evidence to date about the relative importance of these two toxins."

Loyola University Health System

---

---

	Clostridium difficile: A Patient's Guide by Christopher O'Neal (Author), Marianne Khalil (Author), Raf Rizk (Author) Clostridium difficile, a potentially deadly hospital-acquired infection, strikes millions annually around the world. Both the incidence and severity of the disease are growing. A sizable proportion of patients who acquire a C. difficile infection will suffer from repeated recurrences of the disease. This book is meant to educate patients, their families, and their doctors about this growing infectious threat.
	Clostridium difficile: Methods and Protocols (Methods in Molecular Biology) by Peter Mullany (Editor), Adam P. Roberts (Editor) Clostridium difficile, a major nosocomial pathogen shown to be a primary cause of antibiotic-associated disease, has emerged as a highly transmissible and frequently antibiotic-resistant organism, causing a considerable burden on health care systems worldwide. In Clostridium difficile: Methods and Protocols, expert researchers bring together the most recently developed methods for studying the organism, including techniques involving isolation, molecular typing, genomics, genetic manipulation, and the use of animal models.  Written in the highly successful Methods in Molecular Biology™ series format, chapters include brief introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes...
	Bacteria for Breakfast: Probiotics for Good Health by PhD, RPh Kelly Dowhower Karpa (Author) Although in Western society the beneficial aspects of bacteria have been increasingly minimized, we actually need bacteria in our digestive tracts for good health. This resource explains, to laymen and physicians, how probiotics support immune function, prevent urogenital infections, and maintain good gastrintestinal health.
	RECURRENT CLOSTRIDIUM DIFFICILE COLITIS: Tackling a tenacious nosocomial infection Clostridium difficile colitis is a common cause of antibiotic-associated ... patients. (Postgraduate Medicine) by JTE Multimedia Antibiotic-associated colitis caused by the bacterium Clostridium difficile is one of the most common nosocomial infections. In this article, Drs Joyce and Burns explore the conditions that allow C difficile colitis to occur and the reasons that it is so difficult to eradicate. They suggest treatment methods to kill vegetative spores, restore normal colonic flora, and avoid the development of bacterial resistance. Joyce AM, Burns DL. Recurrent Clostridium difficile colitis. Original Publication Date: November 2002
	What You Always Wanted To Know About Clostridium Difficile (Medical Basic Guides) by Jazzybee Publishing "What You Always Wanted To Know About..." are fully researched, straight-to-the-point, easily understandable and most comprehensive medical guides for everybody. Whether you are just interested in the topic of the book or you are directly affected by it, these books can really help you with the information you need. All books including interactive tables-of-contents, this is your step toward new insights and informations. The contents of this book: Who is most likely to get C. diff infection? Can C. diff infection be treated? What are some of the things that hospitals are doing to prevent C. diff infections? What can I do to help prevent C. diff infections? Can my friends and family get C. diff when they visit me? What do I need to...
	Clostridium difficile (Current Topics in Microbiology and Immunology) by K. Aktories (Editor), T.D. Wilkins (Editor) Clostridium difficile has been recognized as the cause of a broad spectrum of enteric disease ranging from mild antibiotic-associated diarrhea to pseudomembranous colitis. This volume gives new insights into the microbiology, diagnostics and epidemiology of Clostridium difficile and describes recent strategies in treatment of diseases caused by this agent. Main parts of the volume are devoted to Clostridium difficile toxins A and B which are the major virulence factors. The molecular biology, biochemistry, pharmacology and cell biology of these toxins which are the prototypes of a new family of large clostridial cytotoxins is described in great detail. Clostridium difficile toxins act as glucosyltransferases to inactivate small GTP-binding proteins of the Rho family which are involved in...
	Clostridium Difficile: Its Role in Intestinal Disease by Author Unknown (Author) Despite the tremendous progress made during the last few years in understanding the pathogenesis, epidemiology, diagnosis, and treatment of Clostridium difficile-associated intestinal disease, many extremely important and fundamental questions remain to be answered. The objectives of this book are to summarize the available information regarding Clostridium difficile and its role in intestinal disease and to serve as a basis for future investigations in this challenging area. Clostridium difficile: its role in Intestinal Disease. An excellent volume that should appeal not only to the devotee of C difficile but to all gastroenterologists and microbiologists, this will not languish on my library shelves like so many other books I have reviewed. It will be regularly thumbed. --R.H....
	Clostridium Difficile Clostridium Difficile Table of Contents - Introduction - Pathophysiology - Statistics - History - Physical Exam - Workup - Medical Treatment - Surgical Treatment - Relapse
	Leukemoid reaction due to Clostridium difficile infection in acquired immunodeficiency syndrome: two case reports and a review of the literature.(Case ... An article from: Southern Medical Journal by Frederico G.S. De Toledo (Author), Stephen N. Symes (Author) This digital document is an article from Southern Medical Journal, published by Southern Medical Association on April 1, 2004. The length of the article is 3580 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Leukemoid reaction due to Clostridium difficile infection in acquired immunodeficiency syndrome: two case reports and a review of the literature.(Case Report) Author: Frederico G.S. De Toledo Publication: Southern Medical Journal (Refereed) Date: April 1, 2004 Publisher: Southern Medical Association Volume: 97 Issue: 4 Page: 388(5) Distributed by...
	Levofloxacin, cefazolin boost risk for C. difficile diarrhea.(Clostridium difficile): An article from: Internal Medicine News by Mitchel L. Zoler (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on July 1, 2004. The length of the article is 571 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Levofloxacin, cefazolin boost risk for C. difficile diarrhea.(Clostridium difficile) Author: Mitchel L. Zoler Publication: Internal Medicine News (Magazine/Journal) Date: July 1, 2004 Publisher: International Medical News Group Volume: 37 Issue: 13 Page: 74(1) Distributed by Thomson...